New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Research output: Patent

Andreas Kjaer (Inventor), Morten Persson (Inventor), Michael Ploug (Inventor)

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

Original languageEnglish
IPCC07K 16/ 30 A I
Patent numberCN104768573
Priority date03/05/2013
Priority numberWO2013DK50126
Publication statusPublished - 8 Jul 2015

ID: 178221226